DNLI News and Press, Denali Therapeutics Inc. From 05/05/22

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial re...

Denali Therapeutics (NASDAQ:DNLI) said its partner Sanofi (SNY) began dosing in a phase 2 of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS). Under the collaboration agreement, South San Francisco, Calif.-based Denali will receive $40M as milestone payment...

Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS) Denali to receive a milestone payment of $40 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcus Biosciences (NYSE: RCUS ): Cancer biotech having multiple big-pharma collaborations that ensure revenue streams Vir Biotechnology  (NASDAQ: VIR ): Diversified infectious disease play BioNTech (N...

Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At Oppenheimer 32nd Annual Healthcare Virtual Conference - Slideshow

Denali Therapeutics (NASDAQ:DNLI), a clinical-stage biotech focused on neurodegenerative diseases, announced on Tuesday that the company’s Chief Operating Officer Alexander Schuth would add the Chief Financial Officer role to his current responsibilities. A decision by the current CFO,...

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Stev...

Denali Therapeutics (NASDAQ:DNLI) said dosing began in a phase 1/2 trial of DNL593 to treat a type of dementia called frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN). Denali has partnered with Takeda Pharmaceutical (NYSE:TAK) to co-develop and co-commerc...

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that dosi...